5/14/2025

Diphenhydramine Injection

Products Affected - Description

- Diphenhydramine injection, Mylan Institutional (Viatris), 50 mg/mL, 10 mL vial, 10 count, NDC 67457-0124-10 - discontinued

Reason for the Shortage

- Armas has diphenhydramine injection available.
- Fresenius Kabi has diphenhydramine injection available.
- Hikma has diphenhydramine injection available.
- Sagent has diphenhydramine injection available.
- Viatris discontinued diphenhydramine injection in December 2024.

Available Products

- Diphenhydramine injection, Armas Pharmaceuticals, 50 mg/mL, 1 mL vial, 5 count, NDC 72485-0101-05
- Diphenhydramine injection, Armas Pharmaceuticals, 50 mg/mL, 1 mL vial, 25 count, NDC 72485-0101-25
- Diphenhydramine injection, Fresenius Kabi, 50 mg/mL, 1 mL Simplist syringe, 10 count, NDC 76045-0102-10
- Diphenhydramine injection, Fresenius Kabi, 50 mg/mL, 1 mL vial, 25 count, NDC 63323-0664-01
- Diphenhydramine injection, Hikma, 50 mg/mL, 1 mL vial, 25 count, NDC 00641-0376-25
- Diphenhydramine injection, Sagent, 50 mg/mL, 1 mL vial, 25 count, NDC 25021-0481-01

Estimated Resupply Dates

- All marketed presentations are available.

Updated

Updated May 14, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created March 14, 2022 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.